Abstract
Stereotactic body radiation therapy (SBRT) of localized prostate cancer is an investigational therapy that offers practical and perhaps radiobiologic advantages over conventionally fractionated radiation therapy for this disease. In this update of a prospective, phase II trial, we present patient-reported health-related quality of life (HRQOL), toxicity, and disease control outcomes following SBRT monotherapy for low-risk prostate cancer utilizing (1) Varian Trilogy for volumetric setup verification and intensity modulated stereotactic radiation therapy and (2) the Real-time tracking system 4D Localization System for real-time electromagnetic target tracking.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
